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Abstract 
Fibroblast growth factor 1 gene - FGF1 - is expressed primarily in the kidney and is postulated to 
contribute to hypertension. However, the biological mechanisms underlying the association between 
FGF1 and blood pressure regulation remain unknown.  
We report that the major allele of FGF1 single nucleotide polymorphism rs152524 was associated in a 
dose-dependent manner not only with systolic blood pressure (P=9.65x10
-5
) and diastolic blood 
pressure (7.61x10-3) in a meta-analysis of 14364 individuals but also with renal expression of FGF1 
mRNA in 126 human kidneys (9.0x10-3). Next-generation RNA-sequencing revealed that renal up-
regulation of FGF1 expression globally and of each of its 3 mRNA isoforms individually is associated 
with higher blood pressure. FGF1-stratified co-expression analysis in 2 separate collections of human 
kidneys identified 126 FGF1 partner mRNAs, of which 71 and 63 showed at least nominal association 
with systolic and diastolic blood pressure, respectively. Of those, 7 mRNAs in 5 genes (MME, 
PTPRO, REN, SLC12A3 and WNK1) had strong prior annotation to blood pressure or hypertension. 
MME (that encodes an enzyme responsible for degradation of circulating natriuretic peptides) showed 
the strongest differential co-expression with FGF1 between hypertensive and normotensive kidneys. 
Higher level of renal FGF1 expression was associated with lower circulating levels of atrial and brain 
natriuretic peptides.  
These findings indicate that FGF1expression in the kidney is at least under partial genetic control and 
that renal expression of several FGF1 partner genes in natriuretic peptides catabolism pathway, renin-
angiotensin cascade and sodium handling network may explain the association between FGF1 and 
blood pressure. 
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Introduction 
Essential hypertension is a net product of genetic factors and environmental exposure acting together 
on regulatory systems in key organs for blood pressure (BP) homeostasis. The kidney is central to BP 
regulation and drives the development of hypertension through numerous mechanisms including 
glomerular haemodynamics, tubular reabsorption of sodium, actions of renin-angiotensin system and 
natriuretic peptides1. Rare genetic variants that affect expression of molecules and pathways operating 
within the kidney lead to elevated BP in monogenic forms of hypertension
2
. Several common variants 
in genes associated with BP and/or susceptibility to hypertension are also believed to act through the 
renal mechanisms3-7. Two of these variants map to the same fibroblast growth factor 1 signalling 
cascade – a pathway increasingly recognised as an important player in cardiovascular system
6-7
. 
Indeed, common alleles of fibroblast growth factor 1 gene (FGF1) and its chaperone molecule gene 
(fibroblast growth factor binding molecule – FGFBP1) co-segregated with familial susceptibility to 
hypertension in our previous studies
6-7
. The central gene of this pathway – FGF1 – was up-regulated 
at both mRNA and protein level in the hypertensive kidney6-7. The recent large scale genetic analysis 
showed that genetic score composed of FGF1 signalling pathway single nucleotide polymorphisms 
(SNPs) provides a better explanation for variance in hypertension risk than the score calculated using 
a similar number of top variants identified by genome-wide association study8. Taken together, these 
data clearly suggest that FGF1 and its partner molecules play a role in genetic susceptibility to 
hypertension, possibly through kidney-related mechanisms. However, the exact biological cause of 
the association between FGF1 and BP regulation remains unknown.  
 
Here we examined the association between a common SNP of FGF1 and BP in a meta-analysis of 
≈15,000 individuals from 5 populations of white European ancestry. We then explored an effect of 
this SNP on expression of FGF1 mRNA in the largest to date analysis of 126 human kidneys collected 
in in the TRANScriptome of renaL humAn TissueE (TRANSLATE) Study. Through next-generation 
RNA-sequencing (RNA-seq) of human renal tissue we have investigated the network of most likely 
renal partner genes and transcripts of FGF1. Through further clinical association studies, in silico 
analyses and the investigations of biochemical read-outs of the most relevant partner molecules we 
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have identified a biologically plausible network of transcripts that can mediate renal FGF1-related BP 
effect. 
 
Results 
A common SNP of FGF1 (rs152524) is associated with blood pressure in the meta-analysis of 5 
populations 
The major demographic and clinical characteristics of 14364 individuals from 5 populations are given 
in Table 1. Distribution of rs152524 genotypes did not violate Hardy-Weinberg equilibrium6 in either 
of the cohorts and the minor allele frequency of rs152524 in all studies was typical for white 
European population (Table S1). There was at least nominally significant association between 
rs152524 and SBP in 4 out of 5 studies. The meta-analysis of all individuals with available genotypic 
and phenotypic information revealed a significant association between clinic SBP and rs152524 – its 
each major allele copy increased SBP by ≈0.9 (±0.2) mmHg (P=9.65x10-5) (Figure 1). The association 
between rs152524 and clinic DBP was directionally similar but the magnitude of the phenotypic 
effect of the SNP was smaller (P=7.61x10-3) (Figure 1). 
 
Major allele of rs152524 is associated with up-regulation of FGF1 mRNA in the human kidney  
Clinical characteristics of 126 TRANSLATE Study individuals with informative genotype included in 
quantitative real-time PCR analysis of renal FGF1 are given in Table 1. rs152524 was associated with 
renal expression of total FGF1 – compared to the reference genotype (rare homozygous), carriers of 
one and two copies of major allele of rs152524 had 1.8 and 2.7-fold higher (respectively) levels of 
FGF1 mRNA in the kidney (P=0.009) (Figure 2).  
 
Potential transcriptional activity of rs152524 and its statistical proxies – Roadmap Epigenomics and 
ENCODE analysis in silico  
rs152524 maps to the segment of FGF1 intron 1 showing histone modifications in cells from adipose 
tissue, brain and skin indicating that the region may act as a transcriptional enhancer (Table S2). In 
addition, the rs152524-containing part of FGF1 intron 1 is a deoxyribonuclease I (DNase I) 
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hypersensitivity site (DHS), contains a HOXA5 transcription factor binding site and both alleles of 
rs152524 are predicted to show differential effect on binding of HOXA5. The rs152524 has at least 
five statistically similar (r
2
>0.8) SNPs, of which 3 lie within regulatory enhancer regions identified in 
several human tissues (Table S2). The strength and quality of regulatory annotations for all proxy 
SNPs was lesser than that for rs152524 (Table S2). All detected proxies are located within the FGF1 
gene but none of them map to any of four previously reported promoters in 5’ region of FGF1
9-11
. No 
other known SNPs within a 1 Mb distance of rs152524 may account for the detected associations 
through linkage disequilibrium (LD) with rs152524 (Figure S1). 
 
Increased expression of FGF1 and its three renal mRNA isoforms is associated with hypertension and 
higher blood pressure - next-generation RNA-sequencing of human kidney transcriptome  
The available characteristics of individuals whose renal samples underwent next-generation RNA-seq 
are shown in Table S3. A total of 54043 mRNAs mapping to 18677 genes were expressed in 32 
human kidneys from TRANSLATE Study. The RNA-seq identified 3 mRNA isoforms of FGF1 and 
revealed that FGF1-001 was the major transcript accounting for 78.5% of detectable renal FGF1 
(Figure 2). The abundance of two other FGF1 transcripts (FGF1-003 and FGF-006) was lower at 
10.3% and 11.2% (respectively) (Figure 2). The expression of all FGF1 transcripts showed a high 
level of linear inter-correlation (Table S4). The percentage abundance of FGF1 mRNA isoforms and 
their co-expression patterns were largely replicated in an independent collection of 70 apparently 
healthy renal tissues from The Cancer Genome Atlas (TCGA) project (Figure 2, Table S5). 
 
Both FGF1 globally and its 3 mRNAs separately were ≈31-37% more abundant in hypertensive than 
normotensive kidneys from TRANSLATE Study (where appropriate phenotypic information was 
available) (Table S6). Consistently, the expression of total FGF1 and its 3 renal mRNA isoforms was 
associated with clinic BP in the expected direction (Table 2). 
 
 
 
Page 7 of 54
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
7 
 
Renal FGF1 shows a very high level of co-expression with over 100 mRNAs in the human kidney   
After correction for multiple testing (false discovery rate q<0.1%) a total of 747 mRNAs collapsed to 
506 genes showed association with renal expression of FGF1 in TRANSLATE Study (Figure S2). A 
total of 126 non-FGF1 transcripts in 101 genes associated with FGF1 in TRANSLATE population 
replicated at a conservative FDR<0.1% in the TCGA (Figures 3,S3, Table S7). There was an excellent 
consistency in both average expression and the magnitude of association with FGF1 for those 
transcripts between the discovery and the replication population (Figure 2, Figure S4).  
 
Renal transcripts co-expressed with FGF1 mRNA are associated with BP and have a strong relevance 
to human hypertension 
Of 126 non-FGF1 mRNAs correlated with expression of FGF1 in kidneys, 71 and 63 showed at least 
nominal association with SBP and DBP, (respectively) in TRANSLATE Study (Table S8). This 
translates into 57 and 51 individual genes whose mRNAs are associated with SBP and DBP. Five 
genes (membrane metallo-endopeptidase gene - MME, protein tyrosine phosphatase, receptor type, O 
gene - PTPRO, renin gene - REN, solute carrier family 12 (sodium/chloride transporters), member 3 
gene - SLC12A3 and WNK lysine deficient protein kinase 1 gene - WNK1) associated with BP in the 
study and tightly co-expressed with FGF1 had direct prior annotation to BP regulation either through 
Gene Ontology or by manual data mining (Table S9). The direction of association between the renal 
expression of these five genes and FGF1 abundance as well as BP was positive – the higher their 
expression, the higher renal abundance of FGF1 and the higher BP.  In silico exploration of the 
existing datasets of renal expression profiling revealed that similar to FGF1, MME and PTPRO have 
the strongest enrichment for expression in the glomeruli (Table S10). Further comparative co-
expression analysis revealed that hypertensive kidneys exhibit much stronger co-regulation between 
MME transcripts and FGF1 mRNA than normotensive ones (Figure 2). 
 
Renal up-regulation of FGF1 mRNA is associated with lower circulating levels of natriuretic peptides  
In 32 subjects whose kidney samples underwent next-generation RNA sequencing renal expression of 
FGF1 showed negative correlation with circulating levels of brain natriuretic peptide (BNP) (r=-
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0.359, P=0.044). This association retained its statistical significance after adjustment for other clinical 
variables (β=-0.022, SE=0.009, P=0.023). Circulating levels of pro-atrial natriuretic peptide (proANP) 
showed the same direction of correlation (r=-0.287, P=0.111). Upon specified criteria, renal FGF1 
mRNA showed a negative association with circulating proANP in multiple regression analysis (β=-
0.018, SE=0.009, P=0.057). The direction of associations between serum concentrations of both 
natriuretic peptides and renal expression of MME mRNA was similar to that of FGF1 mRNA but the 
level of statistical significance of these associations was somewhat weaker in multiple regression 
analysis (P=0.083 and P=0.138 for proANP and BNP, respectively). FGF1 showed also positive 
association with natriuretic peptide receptor 3 (NPR3) at the renal expression level (P=3.4x10
-8
).  
 
Discussion 
Our study has provided several important new insights into the association between FGF1 and BP. 
Firstly, we revealed that the common allelic variant of FGF1 previously associated with familial 
susceptibility to hypertension is also related to BP as a continuous quantitative trait in a large sample 
of individuals recruited primarily from the general populations. Secondly, we provided data 
suggestive of an effect of this variant on FGF1 mRNA in the kidney. Thirdly, through next-generation 
RNA-sequencing we have characterised the diversity of renal FGF1 mRNAs and quantified the extent 
of their over-expression in hypertensive kidney. Most importantly, through co-expression analysis we 
have identified the network of FGF1 partner transcripts and genes that may explain how up-regulation 
of FGF1 mRNA in the kidney could relate to BP elevation.  
 
FGF1 was identified as a strong positional and potentially functional candidate gene for hypertension 
in our previous studies combining linkage analysis with fine mapping, rat-human synteny and direct 
sequencing6,12. Our subsequent family-based association analysis revealed that a major allele of 
common FGF1 SNP (rs152524) was transmitted from heterozygous parents to essentially 
hypertensive offspring more frequently than expected by chance
6
. The data presented here clearly 
demonstrate that rs152524 is also associated with both SBP and DBP as continuous traits and that the 
direction of allelic association with BP is concordant with that observed for hypertension. As expected 
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from a common SNP, the magnitude of the allelic effect on BP is small (≈0.9 mmHg increase in SBP 
per major allele copy), consistent with the findings on common variants associated with BP in large 
genetic meta-analyses
3
. However, in contrast to many genetic associations identified before, the 
relationship between rs152524 and BP has biologically meaningful functional context – a major allele 
of rs152524 not only correlated with BP elevation but also – an increase in renal expression of FGF1 
mRNA. Further studies will be needed to confirm that rs152524 acts as cis-acting gene expression 
Quantitative Trait Locus (cis-eQTL) for FGF1 in the kidney. Our previous direct sequencing studies 
excluded common SNP within the coding sequences of FGF1 that could account for the detected 
associations by i.e. LD with rs152524
6
. The rs152524 maps to a putatively regulatory segment of 
FGF1 intron 1 in several tissues; the absence of kidneys in ENCODE and Roadmap Epigenomics did 
not permit us to explore potential regulatory role of rs152524 in tissue relevant to our study. It is 
tempting to surmise that the characterised region in intron 1 may operate as an enhancer and possibly, 
in concert with previously identified alternative promoters9-11, contribute to transcriptional regulation 
of FGF1. Indeed, four different promoters in 5’ region of FGF1 were reported to control its 
transcription into four different mRNA isoforms in cell/tissue-specific manner9-11. 5’ regions of two 
FGF1 mRNA isoforms identified in our next-generation RNA-sequencing experiment as FGF1-003 
and FGF1-006 best overlap with sequences regulated by promoter 1A whilst FGF1-001 – with 
promoter 1D9-11. FGF1 promoter 1A was reported as operational in the kidney and promoter 1D was 
identified as active in vascular smooth muscle cells (VSMC) and fibroblasts11. Both fibroblasts and 
VSMC are resident cells of the human kidney
13
. However, we should acknowledge the inherent 
limitation of selection of poly-adenylated RNA molecules in sample preparation – the use of this 
biochemistry is known to lead to 3’ bias in RNA-sequencing experiments, thus fine-scale 5’ promoter 
usage may be more challenging to resolve
14-15
. 
The kidney is a key organ for BP regulation and the site of highest FGF1 expression 
(http://www.proteinatlas.org/ENSG00000113578/tissue). FGF1 belongs to one of glomerulus-
enriched genes
16-19 
and both our and others’ previous immunochemistry confirmed the exclusive 
expression of FGF1 within apparently normal human glomeruli6,20. A number of mRNAs (i.e. 
Nephrosis 1, congenital, Finnish type (nephrin) gene - NPHS1, Nephrosis 2, idiopathic, steroid-
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resistant (podocin) gene - NPHS2) most tightly co-expressed with FGF1 in kidneys examined here are 
known as key structural constituents of glomerulus21. Taken together these data suggest that the main 
direct biological actions of FGF1 in the kidney occur in glomeruli. Given a diversity of biological 
processes that FGF1-co-expressed mRNAs map onto, we suspect that FGF1 may be involved in 
regulation of structural integrity of glomeruli and renal maintenance of metabolic homeostasis. 
 
FGF1 is a strong mitogenic signalling molecule22 but the mechanisms underlying its association with 
BP are not clear. Given that levels of mRNA/gene co-expression are good measures for activity of 
networks that control complex genetic mechanisms
23
, we used renal next-generation RNA-seq data to 
identify FGF1 partner molecules and elucidate how increased expression of FGF1 in the kidney may 
link to BP regulation. Of FGF1 co-expressed mRNAs, those associated with SBP and/or DBP in the 
TRANSLATE Study and having direct prior annotation to BP regulation are the strongest putative 
mediators of FGF1-related BP effect. Indeed, four of these genes (REN, MME, WNK1 and 
SLC12A3) belong to key BP regulatory cascades and three (REN, MME and SLC12As) are direct 
targets for antihypertensive medications. MME encodes membrane metallo-endopeptidase (neutral 
endopeptidase or neprilysin) – an enzyme responsible for biochemical degradation of circulating 
peptides many of which promote vasodilation and/or natriuresis i.e. bradykinin, ANP and BNP
24
. 
Pharmacological inhibition of neprilysin leads to increased levels of natriuretic peptides and was 
proposed as a blood pressure lowering therapy24. Indeed, hypertension is increasingly recognised as a 
state of ANP and BNP deficiency
24
. Similar to FGF1, MME is highly expressed within renal 
glomeruli25. Renin is responsible for cleavage of angiotensin I from angiotensinogen - a rate-limiting 
step in activation of a fundamental pathway of BP regulation26. The products of WNK1 and SLC12A3 
belong to a key cellular mechanism of sodium reabsorption in the distal convoluted tubule of the 
nephron and their up-regulation is a recognised renal mechanism of hypertension27. Unlike FGF1 and 
MME, REN is expressed primarily within juxto-glomerular apparatus and collecting duct whilst 
WNK1 and SLC12A3 are expressed in the distal nephron
26-27
. Taken together these data indicate that 
increased expression of FGF1 in the kidney correlated with up-regulation of MME, REN, SLC12A3 
and WNK1 transcripts may contribute to BP elevation, potentially through heightened catabolism of 
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natriuretic peptides clearance/degradation (MME), activation of renin-angiotensin cascade (REN) and 
increased sodium reabsorption (SLC12A3 and WNK1). Furthermore, the direction of association 
between renal abundance of MME, REN, SLC12A3 and WNK1 mRNAs and BP in TRANSLATE 
Study (increased expression = higher BP) fits into their potential role as mediators of BP elevating 
effect of FGF1 overexpression. The correlation between decreased circulating levels of key substrates 
(natriuretic peptides) for MME and up-regulation of renal FGF1 further suggests that at least one of 
its identified renal co-expressions translates into biologically active mechanism measurable in the 
systemic circulation. One of the potential explanations for the somewhat weaker associations between 
natriuretic peptides and MME mRNA than those identified between both peptides and FGF1 mRNA 
is that increased renal expression of FGF1 mRNA correlates with up-regulation of another, MME-
independent mechanism of natriuretic peptide catabolism in the kidney. Our data support this 
hypothesis - renal expression of FGF1 showed a positive association with NPR3 mRNA – an 
important clearance receptor for natriuretic peptides. In this context, increased expression of 
glomerular FGF1 may lead to a drop in levels of natriuretic peptides potentially through renal 
activation of their clearance/degradation pathway whilst increased expression of some other FGF1-co-
expressed mRNAs in the kidney (i.e. REN, SLC12A3, WNK4) may simply indicate the activation of 
mechanisms secondary to the reduction in ANP/BNP circulating levels. To this end, lower levels of 
natriuretic peptides are synonymous with the reduction of their inhibitory effect on tubular sodium 
reabsorption and their weaker opposing effect on suppression of renin28. Indeed, our data showed that 
expression of MME mRNA correlates positively with abundance of REN, WNK1 and SLC12A3 
mRNAs in kidneys from both TRANSLATE and TCGA cohorts (Figure 3 and Figure S3 – the most 
inner parts).  
We should acknowledge that given the inherent limitations of our RNA-sequencing experiments, we 
cannot assign the direction to the identified co-expression patterns/associations and/or assess the 
extent to which they are primary (causal) or secondary (reactive). The association between FGF1 
mRNA and its common SNP suggests that at least a proportion of renal increase of FGF1 mRNA is 
genetically regulated. It is also fair to point out that other FGF1-co-related transcripts and genes 
including several non-coding RNAs without prior linkage to BP regulation ontology terms may 
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mediate/contribute to the association between FGF1 and BP. We appreciate the limitations of RNA 
profiling of the kidney as the whole organ17. Indeed, cellular diversity of the kidney may lead to 
variation in transcriptome composition between different segments of the nephron
17
. Single cell 
transcriptomics will be helpful to refine the identified co-expression patterns. Finally, we appreciate 
that our study is based primarily on expression analysis of FGF1 mRNA. Further experiments at the 
protein level will be necessary to confirm our findings. 
 
Within the interpretational limitations discussed above our data suggest that the expression of FGF1 
mRNA in the human kidney is at least partly genetically controlled and that FGF1 maps onto several 
major renal pathways of BP regulation. Our study also illustrates the potential of next-generation 
RNA-seq in relevant human tissues to provide insights into mechanisms underlying associations 
between candidate genes and complex phenotypes.  
 
Concise methods 
Populations 
Five populations (Silesian Cardiovascular Study – SCS29, Victorian Family Heart Study – VFHS30 
Prevention of Renal and
 
Vascular End-stage Disease Study – PREVEND
31-32
, Genetic
 
Regulation of 
Arterial Pressure of Humans in the Community Study – GRAPHIC5,33 and Young Men 
Cardiovascular Association Study – YMCA34) with relevant genetic (directly genotyped rs152524 
SNP) and phenotypic (clinic blood pressure) information were included in the genetic association 
analysis. All individuals were of white European ethnicity.  
 
TRANSLATE Study provided human kidney samples for quantitative real-time PCR analysis of 
FGF1 (n=133) and the discovery phase of the next-generation RNA-sequencing analysis (n=32). In 
brief, the TRANSLATE Study recruited individuals of white European ancestry eligible for unilateral 
elective nephrectomy because of non-invasive renal cancer in three reference centres
7
. Small 
fragments of kidney tissues were collected from healthy (unaffected by cancer) pole of the kidney and 
immersed in RNAlater (Ambion, Austin, TX) immediately after nephrectomy. Information on an 
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additional set of 70 human kidneys characterised by RNA-sequencing used in the replication phase of 
next-generation RNA-sequencing analysis was obtained from TCGA database35. The tissue material 
was secured from tissue unaffected by cancer (healthy control) after renal nephrectomy due to 
cancer36.  
 
The Bioethical Committees have approved the studies and all subjects have given written informed 
consent for participation. The studies adhered to the Declaration of Helsinki. Information on the 
recruitment and phenotyping of each individual study is summarised in the Supplementary material.  
 
DNA analysis  
DNA was extracted from peripheral blood leukocytes according to the previously described 
protocols
5,12,29,34
. In all populations, the SNP of interest was genotyped directly – in GRAPHIC by 
MALDI-TOF mass spectrometry (MassARRAY system, Sequenom Inc.) and in other cohorts - by 
TaqMan (ABI PRISM 7900HT Sequence Detection System - Applied Biosystems). 
 
RNA analysis  
RNA was extracted from kidneys using previously reported protocols
6
. The measurement of total 
FGF1 mRNA in 126 TRANSLATE Study kidneys with informative rs152524 genotype was 
conducted by SYBR® Green-based real-time quantitative PCR on Eppendorf Realplex PCR 
equipment (Eppendorf, Sydney, Australia). The discovery next-generation RNA-sequencing 
experiment in 32 TRANSLATE kidneys was conducted on Illumina HiSeqTM 2000 sequencer 
(Illumina, San Diego, California, USA) using 100-bp paired-end reads. 70 TCGA kidneys were also 
sequenced on an Illumina HiSeq 2000 and raw (level 1) 50 bp reads were downloaded from CGHub 
(https://cghub.ucsc.edu/). 
 
Biochemical studies 
Serum levels of BNP and proANP (1-98) were measured in TRANSLATE individuals who underwent 
renal RNA-seq by direct chemiluminescence on Centaur XP platform (SIEMENS, Munich, Germany) 
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and enzyme immunoassay (BioMedica, Wien, Austria) on Asys Hitech Expert 96 (BIOGENET), 
respectively. 
 
Statistical and bioinformatic analysis 
The analysis of association between rs152524 and treatment-corrected clinic blood pressures was 
conducted by multiple linear regression after adjustment for additional clinical variables and under 
additive model of inheritance in each cohort individually and then jointly in fixed-effects inverse 
variance meta-analysis. The effect of rs152524 on quantitative PCR expression measures of FGF1 
mRNA was examined under the same model of inheritance and after adjustment for demographic and 
technical variables in linear regression. In silico analysis of biological activity of rs152524 was 
conducted using data from Roadmap Epigenomics
37
 and ENCODE
38
. Circulating levels of BNP and 
proANP underwent log- and inverse transformation prior to association studies. Their association with 
RNA-seq measure of FGF1 expression in the kidney were examined by Pearson’s correlation and 
multiple linear regression after adjustment for clinical and demographic parameters. 
The renal RNA sequencing data were processed through the Tuxedo workflow and the ultimate 
abundance of each mRNA was calculated in log2 transcripts per million (TPM) units. Baseline co-
expression analysis with FGF1 was conducted for all renal mRNAs (individually and after collapsing 
to genes) by LIMMA with adjustment for available clinical and demographic variables in both 
TRANSLATE Study and TCGA. The correction for multiple testing calculated by false discovery rate 
was set at 0.1% in both datasets. 
 
The extended version of the statistical and bioinformatics analysis is available in Supplementary 
material. 
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Table 1. Demographic and clinical characteristics of populations.  
Variable SCS VFHS PREVEND GRAPHIC YMCA TRANSLATE 
number of subjects 764 2755 7687 1987 1151 126 
M/F 439/325 1334/1421 3784/3903 1005/982 1151/0 71/55 
Age (years) 55.2±11.8 39.7±15.8 49.5±12.8 39.3±14.5 19.1±3.6 61.1±10.5 
Body mass index (kg/m2) 27.5±4.2 25.1±4.1 26.1±4.2 26.1±4.6 22.8±3.0 27.6±4.4 
Clinic SBP (mmHg) 131.3±19.1 123.3±15.2 129.3±20.3 127.1±17.8 118.0±13.1 136.4±13.5 
Clinic DBP (mmHg) 74.9±11.0 75.7±10.7 75.6±11.2 79.2±11.0 74.2±7.9 83.2±8.0 
Hypertension (%) 549 (71.9) 515 (18.6) 2647 (34.4) 571 (28.7) 120 (10.4) 85 (67.5) 
Antihypertensive treatment (%) 451 (59.0) 222 (8.1) 1219 (15.9) 134 (6.7) 18 (1.6) 74 (58.7) 
Data are counts and percentages or means and standard deviations, SBP – systolic blood pressure, DBP – diastolic blood pressure, SCS – Silesian 
Cardiovascular Study; VFHS – Victorian Family Heart Study, PREVEND – Prevention of Renal and Vascular End-stage Disease Study, GRAPHIC – Genetic 
Regulation of Arterial Pressure of Humans in the Community Study, YMCA – Young Men Cardiovascular Association Study, TRANSLATE – 
TRANScriptome of renaL humAn TissueE Study 
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Table 2. Association between FGF1, its renal mRNAs and blood pressure in TRANSLATE Study – 
next-generation RNA-sequencing analysis of human kidneys. 
mRNA 
SBP DBP 
β-coefficient (SE) P-value β-coefficient (SE) P-value 
FGF1 total 0.85±0.35 0.021 1.15±0.57 0.053 
FGF1-001 0.91±0.36 0.016 1.21±0.58 0.046 
FGF1-003 0.091±0.034 0.0083 0.13±0.06 0.028 
FGF1-006 0.13±0.05 0.016 0.14±0.08 0.092 
Data are β-coefficients, standard errors (SE) and level of statistical significance (P-value) from linear 
regression models wherby clinic blood pressure (adjusted for treatment) was a dependent variable, 
and mRNA expression level (in TPM units) of total FGF1 or its individual mRNAs, age, sex and body 
mass index were independent parameters 
 
Page 24 of 54
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Figure 1. Association between single nucleotide polymorphism of FGF1 (rs152524) and blood pressure in 
14344 individuals from 5 populations. Data are expressed as β-coefficients (Point estimate), with standard 
errors and lower/upper limits of the confid nce intervals together with respective levels of statistical 
significance (P-value); the data come from regression analysis of systolic blood pressure (upper panel) or 
diastolic blood pressure (lower panel) as independent variables together with rs152524 genotype and 
demographic phenotypes as dependent parameters; major allele or rs152524 (A) is a reference allele.  
246x141mm (300 x 300 DPI)  
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Figure 2. Renal expression of FGF1, its main mRNA isoforms and partner mRNAs in the human kidney. A. 
Relative fold differences in expression of total FGF1 mRNA between rs152524 genotypes – quantitative real-
time PCR analysis of 126 human kidneys, P – level of statistical significance, n – number of individuals in 
each genotype group; B. The schematic structure of 3 renal FGF1 mRNA isoforms, 3UTR – 3’ untranslated 
region, 5UTR – 5’ untranslated region, CDS – coding sequence, FGF1-001 and FGF1-006 contain the same 
set of translated exons but differ in the structure of both  5’ and 3’ regions, FGF1-003 is a non-coding mRNA 
with a retained intron; CD. Percentage abundance of FGF1 mRNA isoforms in relation to total renal FGF1 
mRNA in TRANScriptome of renaL humAn TissueE (TRANSLATE) Study (C) and The Cancer Genome Atlas 
(TCGA) resource (D); E. A total of 126 mRNAs co-expressed with FGF1 in the human kidney – consistency in 
the average expression between the discovery population (TRANSLATE Study) and the replication resource 
(TCGA), log2 TPM+1 – unit of expression from next-generation RNA-sequencing; F. Renal co-expression 
between FGF1 and 7 transcripts in 5 genes with highest relevance to blood pressure regulation – comparison 
of hypertensive (H) and normotensive (N) kidneys from the next-generation RNA-sequencing experiment, t-
statistic - the magnitude of pair-wise co-expression calculated from a linear regression and expressed by 
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Figure 3. Replicated partner mRNAs of FGF1 in the kidney – next-generation RNA-sequencing in 
TRANScriptome of renaL humAn TissueE (TRANSLATE) Study. Replicated mRNAs – mRNAs associated with 
expression of FGF1 in both the TRANSLATE Study and The Cancer Genome Atlas resource; outermost circle 
– symbols of 126 mRNAs ordered in circular manner; first circle below – level of renal expression for each 
replicated partner mRNA (in log2 TPM+1 values) whereby white – lowest expression and navy blue – highest 
expression; second circle below – level of co-expression (measured as β-coefficient from linear regression) 
between each partner mRNA and FGF1 mRNA whereby dark brown – strong positive co-expression and 
beige – weak positive co-expression; third circle below – level of statistical significance (measured as –log10 
P-value from linear regression) for co-expression between each partner mRNA and FGF1 mRNA, whereby 
white – strong statistical significance and pink – weak statistical significance; most inner circle – level of 
connectivity of partner mRNAs whereby dark red – highly connective mRNAs, orange – mRNAs with low 
connectivity; inside – co-expression between selected mRNAs relevant to blood pressure regulation.  
1322x1322mm (96 x 96 DPI)  
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2 
 
Extended methods section 
 
Populations 
Silesian Cardiovascular Study (SCS)  
SCS is a cohort of 1138 individuals (213 families with 703 subjects and 435 subjects with no families) 
recruited in Southern Poland through index patients (in families – parents) with high cardiovascular 
risk (defined as hypertension and/or coronary artery disease and/or clustering of multiple 
cardiovascular risk factors), as reported before (1). Each subject underwent
 
thorough clinical, 
anthropometric, and biochemical phenotyping (1). Oscillometric blood pressure (BP) measurements 
were conducted in triplicate and 3 readings were averaged in to estimate the final systolic BP (SBP) 
and diastolic BP (DBP). All biologically unrelated individuals (807 subjects) from the previous FGF 
pathway study (2) were included in this analysis. A total of 764 individuals with complete genotype 
and phenotype information were included in the association analysis.  
 
The Victorian Family Heart Study (VFHS) 
This cohort of families of white European ancestry was recruited from the general population of 
Victoria (Australia) (3). Each of 783 nuclear families consisted of both parents (aged 40-70 years) and 
at least one natural offspring (aged 18-30 years). Phenotyping included taking medical history, 
clinical examination, and blood biochemistry (3). Supine BP was measured after resting (for at least 
10 minutes) using standard sphygmomanometry. Of three BP measurements taken, the last two were 
recorded and averaged in calculation of the final SBP and DBP values. A total of 2755 individuals 
with full genotypic and phenotypic information were included in the genetic association analysis. 
 
Prevention of Renal and
 
Vascular End-stage Disease (PREVEND) Study 
PREVEND cohort consists of biologically unrelated individuals from the adult (age range: 28-75 
years) general population of Groningen (the Netherlands) unselected for hypertension but enriched for 
microalbuminuria, as reported before (4-5). In brief, 40856 subjects who responded to invitation to 
participate were screened for microalbuminuria. A total of 7768 individuals with urinary albumin 
concentration of ≥10mg/L together with 3395 subjects randomly selected from amongst those who 
had urinary albumin concentration of <10 mg/L were invited for further investigations in an outpatient 
clinic (4-5). A total of 8592 subjects who completed the screening program were included in the study 
group. Of those individuals of non-European ancestry and those with missing DNA were excluded 
prior to genotyping. BP was measured automatically in a supine position using automatic method 
(Dinamap XL Model 9300) during 2 clinic appointments. The mean of the last two measurements 
taken at the two visits was used in calculation of the final SBP and DBP values (4-5). Complete 
genotype and phenotype information was available for 7687 individuals. 
 
Genetic Regulation of Arterial Pressure of Humans in the Community (GRAPHIC) Study  
The details of recruitment, phenotyping and general clinical characteristics of GRAPHIC subjects 
were reported before (6-7). In brief, white British nuclear families with both parents (aged 40-60 
years) and two adult offspring (aged ≥18 years) were identified through general practices in 
Leicestershire (UK) and invited to participate. There were no exclusion criteria apart from a known 
history of renal disease. A total of 2037 subjects from 520 nuclear families underwent detailed clinical 
phenotyping including medical history, anthropometric measurements, extensive blood biochemistry, 
along with BP measurements (7). Clinic BP was measured in triplicate using automatic device 
(Omron HEM-705CP monitors) and the mean of the second and third readings was used in calculation 
of the final values of SBP and DBP. A total of 1987 individuals with complete genetic and phenotypic 
data were included in the association analysis.   
 
Young Men Cardiovascular Association (YMCA) Study 
This cohort of 1157 young (average age: 19 years) men was recruited in Silesia (Southern Poland) (8). 
In brief, apparently healthy men of white European ancestry with no prior history of cardiovascular 
disease (apart from hypertension) were recruited from secondary schools of Silesia. As a part of 
phenotyping demographic and clinical information was collected using standardised coded 
questionnaires prior to anthropometric measurements and biochemical analyses (8). Blood pressure 
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3 
 
was measured in a sitting position using calibrated mercury sphygmomanometer (8). Three readings 
were averaged in calculation of the final SBP and DBP values (8-9). A total of 1151 men were fully 
informative in the genetic association analysis.  
 
TRANScriptome of renaL humAn TissueE (TRANSLATE) Study  
TRANLSATE Study provided human kidney samples both for quantitative real-time PCR analysis of 
FGF1 (n=133) and the discovery phase of the next-generation RNA-sequencing analysis (n=32).  
Human kidney samples from the TRANSLATE Study were collected after surgery in 133 patients 
who underwent elective unilateral nephrectomy because of non-invasive renal cancer in one of three 
nephrology-urology centres [Silesian Renal Tissue Bank (2,10), TRANSLATE P (recruitment 
conducted in Western Poland) and TRANSLATE Z (recruitment conducted in Southern Poland)]. 
Small fragments of kidney tissues were collected from healthy (unaffected by cancer) pole of the 
kidney and immersed in RNAlater (Ambion, Austin, TX) immediately after nephrectomy (2). Each 
subject underwent standardised clinical phenotyping, including personal history (through anonymous 
coded questionnaires), anthropometry (weight, height) and triplicate measurements of BP using a 
mercury sphygmomanometer (in a subset of samples – Silesian Renal Tissue Bank) (2,10) or 
automatic digital BP monitoring (in the rest of the patients). Diagnosis of hypertension was based on 
BP values ≥140/90 mmHg (measured on at least two separate occasions) and/or being on 
pharmacological anti-hypertensive treatment.  
 
All recruited individuals were of white European ancestry. 
 
RNA analysis  
Renal expression of FGF1 mRNA - SYBR® Green-based real-time quantitative PCR  
The sequences of human FGF1 mRNA was obtained from Ensembl database. Primer3Plus software 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) and PrimerQuest 
(https://www.idtdna.com/Scitools/Applications/Primerquest/Default.aspx) were used to design 
primers for total FGF1 - the primers were designed based on the sequence of the first coding exon of 
FGF1 and capture all other known transcripts. Quantitative real-time PCR (qPCR) of renal samples 
from TRANSLATE Study was performed on Eppendorf Realplex PCR equipment (Eppendorf, 
Sydney, Australia). The experiments were conducted using 5 µl SensiMix SYBR No-ROX (Bioline, 
Sydney, Australia), 0.25 µl of each specific primer (GeneWorks, Adelaide, South Australia), 1 µl of 
renal cDNA (100 ng) and H2O to a final 10 µl volume. qPCR was carried out over 45 cycles of 95ºC 
for 15 sec, 57ºC for 15 sec, and 72ºC for 15 sec. The relative level of target gene expression was 
normalized to 18s ribosomal RNA.  
 
Sequencing library preparation - TRANSLATE Study 
Sequencing libraries were generated from 1 µg of total RNA for each sample and by following the 
Illumina TruSeq RNA sample preparation guide version 2 protocol. This protocol included poly-A 
transcript selection (via oligo-dT beads) and random hexamer primed first strand cDNA synthesis. 
 
Statistical and bioinformatics analysis 
Genetic association analysis 
The concordance of rs152524 genotypes distribution with Hardy-Weinberg equilibrium was examined 
using a χ
2
 test under the previously used threshold of P<0.01 (2,10). 
Prior to association analysis, a correction for BP lowering effect of antihypertensive medication was 
applied - in all patients on pharmacological treatment a constant of 15 mmHg and 10 mmHg was 
added to measured SBP and DBP (respectively), similar to the algorithm used by International 
Consortium for Blood Pressure Genome-Wide Association Studies (9). 
The analysis of association between BP and rs152524 in biologically unrelated subjects (SCS, 
PREVEND, YMCA) was conducted by linear regression under additive model of inheritance (coded 
as 0, 1 or 2 major allele copies). The regression models were constructed in PLINK and adjusted for 
age and sex (11). In VFHS families the association analysis was examined under the same model of 
inheritance using the PLINK family-based test for quantitative traits (QFAM) (12). The QFAM 
regressed age, age
2
 and sex-adjusted SBP and DBP on rs152524 genotype and corrected for family 
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4 
 
structure using adaptive permutations (12). The association analysis in the GRAPHIC cohort was 
carried out by GEMMA software that uses Mixed Model Association algorithm for a standard linear 
mixed model and some of its close relatives (13). GEMMA fitted linear mixed models (LMM) for 
association tests of rs152524 with SBP and DBP (accounting for family structure) In GRAPHIC 
Study. The analysis was also adjusted for age, age
2
 and sex.  
In all models β-coefficients along with the respective standard errors (SE) were calculated per each 
major allele copy of rs152524. Inverse variance weighted averages of β-coefficients and SE from all 
populations were pooled together in fixed effects meta-analysis. A combined effect size estimates and 
respective p-values were calculated for the effective sample of 14364 individuals under additive 
model of inheritance using METAL software 
(http://www.sph.umich.edu/csg/abecasis/metal/index.html). The between-study heterogeneity was 
computed using χ
2
-test. 
 
rs152524 – renal FGF1 mRNA association analysis  
The compatibility of rs152524 genotypes distribution with Hardy–Weinberg Equilibrium was tested 
by χ2 test. The effect of rs152524 on renal expression of total FGF1 mRNA was examined by 
regressing the qPCR-derived measure on rs152524 genotype (coded as 0, 1 or 2 major allele copies). 
The analysis was conducted by stepwise regression with clinical (age, sex, body mass index – BMI, 
hypertension) and technical (cohort origin, qPCR experiment) variables entered into the model under 
the criteria of F-statistic (Probability-of-F-to-enter ≤0.15, Probability-of-F-to-remove ≥0.2). Relative 
differences in expression of total FGF1 between rs152524 genotypes were calculated using 2
-∆∆C
T 
formula (14) whereby ∆CT were residuals for qPCR-derived total FGF1 measures (delta cycle 
thresholds) from stepwise linear regression. Rare homozygous genotype was used as a baseline 
reference. A total of 126 samples were fully informative in genetic-mRNA association analysis.  
 
rs152524 – regulatory analysis in silico 
We investigated the regulatory potential of rs152524 single nucleotide polymorphism (SNP) and its 
statistical proxies [SNPs in high linkage disequilibrium coefficient (r2>0.8) with rs152524]. We 
queried HaploReg v3, a tool that identifies SNPs and their proxies that overlap with regulatory 
regions, for all SNPs showing r
2
-coefficient of at least 0.8 with rs152524. The information for 
transcriptional enhancer regions mapping to FGF1 was obtained from Roadmap Epigenomics (15) 
and ENCODE (16) database on patterns of histone modification, DNase I hypersensitive sites and 
transcription factor binding motifs. 
 
Next-generation RNA-sequencing - TRANSLATE and The Cancer Genome Atlas (TCGA) 
A total of 32 human kidney cDNA libraries from the TRANSLATE study were sequenced on an 
Illumina HiSeq 2000 using 100bp pair-end reads. This resulted in 4.4Gb (±0.48) of mapped sequence 
data per sample. Given an estimated expressed renal transcriptome size of 61.2Mb (see filtering 
below), the average coverage across the transcriptome is 73x. 
 
Raw reads were quality checked using FastQC (17); post-alignment, the squared coefficient of 
variation and expression dispersion estimates were assessed using CummeRBund. Reads were filtered 
and aligned by TopHat v2.0.1 to the Ensembl GRCh37 reference genome using Ensembl v70 
transcript annotations. Cuffdiff v2.1.1 was used to quantify the Ensembl v70 reference transcriptome. 
An assessment of background gene expression noise in the dataset was determined using repeat 
quantification of Ensembl gene structures randomly moved to intergenic locations throughout the 
genome. These quantifications were used to determine a lower cutoff of 0.128 FPKM which accounts 
for 95% of all non-reference genic expression across the dataset.  All transcripts expressed above the 
lower cutoff in 50% or more of the samples were analysed further. Cuffdiff quantifications were 
converted into transcripts per million (TPM) units and then log2 transformed after adding a constant of 
1 (i.e. A TPM of 0 stays at that value after log transformation). Logged TPM values were then 
adjusted using 5 hidden factors defined by probabilistic estimation of expression residuals (PEER), 
using the approach defined earlier (18-19). 
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5 
 
TCGA sample fastq files were downloaded from CGHub (under agreement 26966-1). The TCGA 
samples were sequenced using 50bp paired end reads on an Illuina HiSeq 2000. The raw reads were 
aligned, and transcript expression was quantified, in the same manner as for TRANSLATE. TCGA 
samples were sequenced to greater depth, with 6.8Gb (±1.5Gb) of mapped sequence data per sample 
giving  an average coverage across the transcriptome of 111x (assuming a 61.2Mb transcriptome). 
 
Linear correlations between mRNA isoforms of FGF1 expressed in the kidney were examined by 
Pearson’s linear correlation. The analysis of co-expression between FGF1 mRNA and renal 
transcripts was conducted using multiple linear regression models whereby individual transcripts were 
independent variables and FGF1 mRNA abundance (expressed in TPM units), age, sex and BMI – 
dependent parameters. This analysis was followed by collapsing significantly associated mRNA 
isoforms into genes they originate from. The obtained regression coefficients with the respective SE 
and levels of statistical significance were used as measures of co-expression between FGF1 and other 
mRNA. The correction for multiple testing was applied by estimating the false discovery rate (FDR). 
We used an FDR lower threshold of q=0.001 (0.1%) for detection of statistically significant co-
expressed transcripts, genes and collapsed genes. Circle plots were produced using circos (20) to 
visualise levels of co-expression between FGF1 and correlated transcripts. 
 
Differences in renal expression of total FGF1 mRNA and its mRNA isoforms between hypertensive 
and normotensive kidneys from TRANSLATE Study were calculated by linear regression with 
mRNA expression measures (expressed in TPM) as the dependant variable and age, sex, BMI and 
hypertensive status as independent parameters. Analysis of association between mRNAs and BP in 
the TRANSLATE Study was conducted by the linear regression with SBP/DBP as dependent variable 
and individual mRNAs (or genes where appropriate) expression measures obtained from next 
generation RNA-sequencing, age, sex and BMI as independent parameters.   
 
Biochemical analysis 
Serum levels of natriuretic peptides (proANP and BNP) measured in 32 individuals included in RNA-
seq were normalised by inverse transformation prior to further association studies. Renal expression 
measures of FGF1 mRNA were obtained from next generation RNA-seq. Analysis of association 
between natriuretic peptides and FGF1 expression in the kidney was conducted by stepwise linear 
regression equations whereby natriuretic peptides levels were independent phenotypes and FGF1 
mRNA, age, sex, and BMI – independent variables. The independent parameters were entered in the 
regression models based on F-statistic criterion (Probability-of-F-to-enter ≤0.25, Probability-of-F-to-
remove ≥0.30). 
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Supplementary Tables 
Table S1. Allele frequencies of rs152524 single nucleotide polymorphism in FGF1. 
Study Minor allele frequency (G) Major allele frequency (A) 
SCS 0.45 0.55 
VFHS 0.43 0.57 
PREVEND 0.45 0.55 
GRAPHIC 0.43 0.57 
YMCA 0.45 0.55 
TRANSLATE 0.36 0.64 
SCS – Silesian Cardiovascular Study, VFHS – Victorian Family Heart Study, PREVEND –  
Prevention of Renal and
 
Vascular End-stage Disease Study, GRAPHIC – Genetic
 
Regulation of 
Arterial Pressure of Humans in the Community Study, YMCA – Young Men Cardiovascular 
Association Study, TRANSLATE – TRANScriptome of renaL humAn TissueE Study; in family-
based studies allele frequencies were calculated based on the data from parental generation 
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Table S2. Regulatory regions overlapping with rs152524 and its proxies in Roadmap Epigenomics 
and ENCODE. 
SNP r2 Tissue/Cell type Regulatory region type Data source 
rs152524 - 
adipose derived 
mesenchymal stem cell 
cultured cells 
weak enhancer 
Roadmap 
Epigenomics 
rs152524 - brain angular gyrus 
enhancer-like 
transcribed region 
Roadmap 
Epigenomics 
rs152524 - imr90 cell line active enhancer 
Roadmap 
Epigenomics 
rs152524 - 
hesc derived cd56+ 
mesoderm cultured cells 
weak enhancer 
Roadmap 
Epigenomics 
rs152524 - 
penis foreskin fibroblast 
primary cells.donor skin02 
transcription enhancer-
like 
Roadmap 
Epigenomics 
rs152524 - brain cingulate gyrus 
transcription enhancer-
like 
Roadmap 
Epigenomics 
rs152524 - fetal muscle trunk 
DNase I hypersensitive 
site 
Roadmap 
Epigenomics 
rs152524 - fetal muscle leg 
DNase I hypersensitive 
site 
Roadmap 
Epigenomics 
rs152524 - T cell  (leukaemia line) Enhancer Ensembl VEP 
rs152524 - mammary epithelial cells Enhancer Ensembl VEP 
rs152524 - skeletal muscle myoblasts Enhancer Ensembl VEP 
rs152524 - fetal lung fibroblasts Enhancer Ensembl VEP 
rs152524 - astrocytes Enhancer Ensembl VEP 
rs152524 - adult dermal fibroblasts Enhancer Ensembl VEP 
rs152524 - epidermal keratinocytes Enhancer Ensembl VEP 
rs152524 - lung fibroblasts Enhancer Ensembl VEP 
rs152524 - osteoblasts Enhancer Ensembl VEP 
rs34012 0.92 fetal brain weak enhancer 
Roadmap 
Epigenomics 
rs34012 0.92 fetal brain 
DNase I hypersensitive 
site 
Roadmap 
Epigenomics 
rs249925 0.85 left ventricle active enhancer 
Roadmap 
Epigenomics 
rs249925 0.85 
chondrocytes from bone 
marrow derived 
mesenchymal stem cell 
cultured cells 
weak enhancer 
Roadmap 
Epigenomics 
rs249925 0.85 stomach mucosa weak enhancer 
Roadmap 
Epigenomics 
rs34005 0.8 
mesenchymal stem cell 
derived adipocyte cultured 
cells 
weak enhancer 
Roadmap 
Epigenomics 
rs34005 0.8 
adipose derived 
mesenchymal stem cell 
cultured cells 
weak enhancer 
Roadmap 
Epigenomics 
rs34005 0.8 muscle satellite cultured cells active enhancer 
Roadmap 
Epigenomics 
rs34005 0.8 
penis foreskin fibroblast 
primary cells 
weak enhancer 
Roadmap 
Epigenomics 
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rs34005 0.8 
hesc derived cd184+ 
endoderm cultured cells 
weak enhancer 
Roadmap 
Epigenomics 
rs34005 0.8 brain cingulate gyrus active enhancer 
Roadmap 
Epigenomics 
rs34005 0.8 pancreatic islets weak enhancer 
Roadmap 
Epigenomics 
rs34005 0.8 brain substantia nigra weak enhancer 
Roadmap 
Epigenomics 
rs34005 0.8 
penis foreskin melanocyte 
primary cells 
weak enhancer 
Roadmap 
Epigenomics 
rs34005 0.8 mammary epithelial cells weak enhancer ENCODE 
rs34005 0.8 lung fibroblasts weak enhancer ENCODE 
SNP – single nucleotide polymorphism, r
2
 – measure of linkage disequillibrium with rs152524 in 
CEU population, VEP – Variant Effect Predictor 
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Table S3. Demographic and clinical characteristics of individuals from TRANSLATE Study and 
TCGA resource included in next generation RNA-sequencing experiment. 
Variable TRANSLATE TCGA 
Number of subjects 32 70 
M/F 19/13 51/19 
Age (years) 59.0±7.6 62.9±12.0 
Body mass index (kg/m
2
) 26.9±4.4 N/A 
Clinic SBP (mmHg) 140.1±15.4 N/A 
Clinic DBP (mmHg) 88.0±7.7 N/A 
Hypertension (%) 18 (50.0) N/A 
Antihypertensive treatment (%) 14 (43.8) N/A 
Data are counts and percentages or means and standard deviations, SBP – systolic blood pressure, 
DBP – diastolic blood pressure, TRANSLATE – TRANScriptome of renaL humAn TissueE Study, 
TCGA – Tissue Cancer Genome Atlas, N/A – not available 
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Table S4. Linear correlation in renal expression of FGF1 mRNA isoforms in TRANSLATE Study – 
next-generation RNA-sequencing analysis.  
 FGF1-001 FGF1-003 FGF1-006 
FGF1 total r=0.95, P<2.2x10
-16
 r=0.97, P<2.2x10
-16
 r=0.95, P<2.2x10
-16
 
FGF1-001 - r=0.86, P=4.6x10-11 r=0.82, P=3.3x10-9 
FGF1-003 - - r=0.94, P<2.2x10-16 
Data are Pearson’s correlation coefficient (r) and levels of statistical significance (P-values), 
TRANSLATE – TRANScriptome of renaL humAn TissueE Study 
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Table S5. Linear correlation in expression of FGF1 mRNA isoforms in TCGA – next-generation 
RNA-sequencing analysis. 
 FGF1-001 FGF1-003 FGF1-006 
FGF1 total r=0.99, P<2.2x10
-16
 r=0.96, P<2.2x10
-16
 r=0.96, P<2.2x10
-16
 
FGF1-001 - r=0.92, P<2.2x10-16 r=0.93, P<2.2x10-16 
FGF1-003 - - r=0.85, P<2.2x10-16 
Data are Pearson’s correlation coefficient (r) and levels of statistical significance (P-values), TCGA – 
Tissue Cancer Genome Atlas 
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Table S6. Association between FGF1, its renal mRNA isoforms and hypertension in TRANSLATE 
Study – next-generation RNA-sequencing analysis of the human kidneys. 
 All subjects Normotension Hypertension Mean crude 
excess 
P-value 
FGF1 total 56.6±7.5 48.5±10.1 63.8±11.1 31.5% 0.041 
FGF1-001 47.6±6.2 40.9±8.5 53.6±9.0 31.2% 0.042 
FGF1-003 4.1±0.6 3.4±0.6 4.7±1.0 36.7% 0.023 
FGF1-006 4.9±0.8 4.2±1.1 5.5±1.3 31% 0.099 
Data are means and standard errors for expression values from next generation RNA-sequencing 
analysis (in TPM units); mean crude excess – average expression excess in hypertension, P-value – 
level of statistical significance for comparison of hypertension and normotension from a linear 
regression model adjusted for age, sex and body mass index, TRANSLATE – TRANScriptome of 
renaL humAn TissueE Study 
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Table S7. Genes whose mRNAs are associated with renal expression of FGF1 in both TRANSLATE and TCGA Studies. 
No. Ensembl gene ID Gene Symbol Gene product name 
1 ENSG00000213963 AC074286.1 Uncharacterized protein 
2 ENSG00000168306 ACOX2 Acyl-CoA oxidase 2, branched chain 
3 ENSG00000167107 ACSF2 Acyl-CoA synthetase family member 2 
4 ENSG00000163631 ALB Albumin 
5 ENSG00000136872 ALDOB Aldolase B, fructose-bisphosphate 
6 ENSG00000178038 ALS2CL ALS2 C-terminal like 
7 ENSG00000162779 AXDND1 Axonemal dynein light chain domain containing 1 
8 ENSG00000112175 BMP5 Bone morphogenetic protein 5 
9 ENSG00000101144 BMP7 Bone morphogenetic protein 7 
10 ENSG00000139971 C14orf37 Chromosome 14 open reading frame 37 
11 ENSG00000104327 CALB1 Calbindin 1, 28kDa 
12 ENSG00000070808 CAMK2A Calcium/calmodulin-dependent protein kinase II alpha 
13 ENSG00000213085 CCDC19 Coiled-coil domain containing 19 
14 ENSG00000129757 CDKN1C Cyclin-dependent kinase inhibitor 1C (p57, Kip2) 
15 ENSG00000112782 CLIC5 Chloride intracellular channel 5 
16 ENSG00000148204 CRB2 Crumbs homolog 2 (Drosophila) 
17 ENSG00000145708 CRHBP Corticotropin releasing hormone binding protein 
18 ENSG00000160202 CRYAA Crystallin, alpha A 
19 ENSG00000172346 CSDC2 Cold shock domain containing C2, RNA binding 
20 ENSG00000136943 CTSL2 Cathepsin L2 
21 ENSG00000165659 DACH1 Dachshund homolog 1 (Drosophila) 
22 ENSG00000181418 DDN Dendrin 
23 ENSG00000130226 DPP6 Dipeptidyl-peptidase 6 
24 ENSG00000013016 EHD3 EH-domain containing 3 
25 ENSG00000164035 EMCN Endomucin 
26 ENSG00000120658 ENOX1 Ecto-NOX disulfide-thiol exchanger 1 
27 ENSG00000187017 ESPN Espin 
28 ENSG00000163586 FABP1 Fatty acid binding protein 1, liver 
29 ENSG00000039523 FAM65A Family with sequence similarity 65, member A 
30 ENSG00000155816 FMN2 Formin 2 
31 ENSG00000153303 FRMD1 FERM domain containing 1 
32 ENSG00000053108 FSTL4 Follistatin-like 4 
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33 ENSG00000160282 FTCD Formiminotransferase cyclodeaminase 
34 ENSG00000130700 GATA5 GATA binding protein 5 
35 ENSG00000121743 GJA3 Gap junction protein, alpha 3, 46kDa 
36 ENSG00000116983 HPCAL4 Hippocalcin like 4 
37 ENSG00000158104 HPD 4-hydroxyphenylpyruvate dioxygenase 
38 ENSG00000123496 IL13RA2 Interleukin 13 receptor, alpha 2 
39 ENSG00000115602 IL1RL1 Interleukin 1 receptor-like 1 
40 ENSG00000027644 INSRR Insulin receptor-related receptor 
41 ENSG00000167755 KLK6 Kallikrein-related peptidase 6 
42 ENSG00000169035 KLK7 Kallikrein-related peptidase 7 
43 ENSG00000136944 LMX1B LIM homeobox transcription factor 1, beta 
44 ENSG00000234456 MAGI2-AS3 MAGI2 antisense RNA 3 
45 ENSG00000196549 MME Membrane metallo-endopeptidase 
46 ENSG00000240666 MME-AS1 MME antisense RNA 1 
47 ENSG00000205358 MT1H Metallothionein 1H 
48 ENSG00000173376 NDNF Neuron-derived neurotrophic factor 
49 ENSG00000163531 NFASC Neurofascin 
50 ENSG00000116044 NFE2L2 Nuclear factor (erythroid-derived 2)-like 2 
51 ENSG00000161270 NPHS1 Nephrosis 1, congenital, Finnish type (nephrin) 
52 ENSG00000116218 NPHS2 Nephrosis 2, idiopathic, steroid-resistant (podocin) 
53 ENSG00000168743 NPNT Nephronectin 
54 ENSG00000162631 NTNG1 Netrin G1 
55 ENSG00000138315 OIT3 Oncoprotein induced transcript 3 
56 ENSG00000171759 PAH Phenylalanine hydroxylase 
57 ENSG00000067225 PKM Pyruvate kinase, muscle 
58 ENSG00000153246 PLA2R1 Phospholipase A2 receptor 1, 180kDa 
59 ENSG00000128567 PODXL Podocalyxin-like 
60 ENSG00000105227 PRX Periaxin 
61 ENSG00000160801 PTH1R Parathyroid hormone 1 receptor 
62 ENSG00000153707 PTPRD Protein tyrosine phosphatase, receptor type, D 
63 ENSG00000151490 PTPRO Protein tyrosine phosphatase, receptor type, O 
64 ENSG00000164520 RAET1E Retinoic acid early transcript 1E 
65 ENSG00000143839 REN Renin 
66 ENSG00000235366 RP11-154C3.2 Uncharacterized protein 
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67 ENSG00000256029 RP11-190A12.7 Uncharacterized protein 
68 ENSG00000258283 RP11-386G11.3 Uncharacterized protein 
69 ENSG00000255509 RP11-445F12.1 Uncharacterized protein 
70 ENSG00000261788 RP11-480G7.1 Uncharacterized protein 
71 ENSG00000230027 RP11-550H2.2 Uncharacterized protein 
72 ENSG00000255895 RP11-656E20.3 Uncharacterized protein 
73 ENSG00000248115 RP11-752D24.2 Uncharacterized protein 
74 ENSG00000263146 RP11-849I19.1 Uncharacterized protein 
75 ENSG00000259969 RP11-999E24.3 Uncharacterized protein 
76 ENSG00000243988 RPS24P17 Ribosomal protein S24 pseudogene 17 
77 ENSG00000136546 SCN7A Sodium channel, voltage-gated, type VII, alpha subunit 
78 ENSG00000100665 SERPINA4 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4 
79 ENSG00000074803 SLC12A1 Solute carrier family 12 (sodium/potassium/chloride transporters), member 1 
80 ENSG00000070915 SLC12A3 Solute carrier family 12 (sodium/chloride transporters), member 3 
81 ENSG00000149452 SLC22A8 Solute carrier family 22 (organic anion transporter), member 8 
82 ENSG00000091137 SLC26A4 Solute carrier family 26, member 4 
83 ENSG00000186335 SLC36A2 Solute carrier family 36 (proton/amino acid symporter), member 2 
84 ENSG00000186198 SLC51B Solute carrier family 51, beta subunit 
85 ENSG00000010379 SLC6A13 Solute carrier family 6 (neurotransmitter transporter, GABA), member 13 
86 ENSG00000092068 SLC7A8 Solute carrier family 7 (amino acid transporter light chain, L system), member 8 
87 ENSG00000137834 SMAD6 SMAD family member 6 
88 ENSG00000167941 SOST Sclerostin 
89 ENSG00000107742 SPOCK2 Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2 
90 ENSG00000184005 ST6GALNAC3 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-
sialyltransferase 3 
91 ENSG00000118526 TCF21 Transcription factor 21 
92 ENSG00000261787 TCF24 Transcription factor 24 
93 ENSG00000069702 TGFBR3 Transforming growth factor, beta receptor III 
94 ENSG00000165685 TMEM52B Transmembrane protein 52B 
95 ENSG00000159173 TNNI1 Troponin I type 1 (skeletal, slow) 
96 ENSG00000118194 TNNT2 Troponin T type 2 (cardiac) 
97 ENSG00000134198 TSPAN2 Tetraspanin 2 
98 ENSG00000092445 TYRO3 TYRO3 protein tyrosine kinase 
99 ENSG00000243284 VSIG8 V-set and immunoglobulin domain containing 8 
Page 43 of 54
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
16 
 
100 ENSG00000060237 WNK1 WNK lysine deficient protein kinase 1 
101 ENSG00000184937 WT1 Wilms tumor 1 
TRANSLATE – TRANScriptome of renaL humAn TissueE Study, TCGA – Tissue Cancer Genome Atlas 
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Table S8. Associations between clinic blood pressure and non-FGF1 mRNAs co-expressed with FGF1 – next-generation RNA-sequencing analysis in 
TRANSLATE Study. 
No Transcript name Ensembl transcript ID SBP  DBP  
   B-coefficient (SE) P-value B-coefficient (SE) P-value 
1 AC074286.1-001 ENST00000397057 0.35 (0.09) 0.0005 0.56 (0.14) 0.0003 
2 AC074286.1-004 ENST00000430416 0.21 (0.13) 0.108 0.41 (0.19) 0.0422 
3 AC074286.1-005 ENST00000443132 0.11 (0.04) 0.0121 0.20 (0.07) 0.0057 
4 ACOX2-013 ENST00000481527 0.74 (0.26) 0.0092 1.08 (0.42) 0.0161 
5 ALB-006 ENST00000484992 1.06 (0.50) 0.0448 1.80 (0.79) 0.0295 
6 ALDOB-001 ENST00000374855 352.84 (122.70) 0.0074 437.69 (203.88) 0.0402 
7 AXDND1-006 ENST00000489080 0.50 (0.17) 0.0065 0.76 (0.27) 0.0089 
8 C14orf37-001 ENST00000267485 0.03 (0.02) 0.0498 0.04 (0.03) 0.1244 
9 CALB1-001 ENST00000265431 13.85 (4.67) 0.006 22.86 (7.28) 0.0038 
10 CAMK2A-001 ENST00000348628 0.01 (0.00) 0.0474 0.01 (0.01) 0.0863 
11 CLIC5-003 ENST00000339561 0.52 (0.21) 0.0215 0.71 (0.35) 0.0494 
12 CLIC5-201 ENST00000544153 0.02 (0.01) 0.0122 0.02 (0.01) 0.0692 
13 CRB2-201 ENST00000373629 0.03 (0.01) 0.0326 0.04 (0.02) 0.0368 
14 CRHBP-001 ENST00000274368 0.80 (0.23) 0.0014 0.97 (0.39) 0.0182 
15 CRYAA-001 ENST00000291554 6.58 (2.53) 0.0145 10.39 (4.00) 0.0144 
16 CRYAA-004 ENST00000398132 2.50 (0.77) 0.0028 4.07 (1.20) 0.0019 
17 CRYAA-005 ENST00000468016 3.11 (1.01) 0.0045 4.73 (1.61) 0.0064 
18 DACH1-001 ENST00000305425 0.04 (0.02) 0.0172 0.06 (0.03) 0.0551 
19 DDN-001 ENST00000421952 0.22 (0.09) 0.0193 0.35 (0.14) 0.02 
20 DPP6-001 ENST00000404039 0.06 (0.03) 0.0334 0.08 (0.04) 0.0434 
21 EHD3-001 ENST00000322054 0.18 (0.08) 0.0228 0.24 (0.12) 0.0604 
22 EHD3-201 ENST00000541626 0.11 (0.04) 0.0128 0.15 (0.07) 0.0306 
23 FMN2-001 ENST00000319653 0.01 (0.00) 0.0103 0.02 (0.01) 0.0085 
24 IL1RL1-002 ENST00000311734 0.13 (0.06) 0.0554 0.23 (0.10) 0.0245 
25 INSRR-001 ENST00000368195 0.03 (0.01) 0.0216 0.05 (0.02) 0.0271 
26 KLK6-003 ENST00000376851 0.19 (0.08) 0.0289 0.32 (0.13) 0.0184 
27 KLK7-001 ENST00000595820 0.04 (0.02) 0.0226 0.06 (0.03) 0.0502 
28 LMX1B-202 ENST00000425646 0.02 (0.01) 0.0175 0.03 (0.01) 0.0403 
29 MAGI2-AS3-002 ENST00000429408 0.01 (0.00) 0.0332 0.01 (0.01) 0.0993 
30 MAGI2-AS3-003 ENST00000414797 0.11 (0.04) 0.0046 0.17 (0.06) 0.0065 
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31 MAGI2-AS3-007 ENST00000452320 0.11 (0.04) 0.013 0.17 (0.07) 0.0168 
32 MME-001 ENST00000460393 3.84 (1.53) 0.0175 5.66 (2.44) 0.0276 
33 MME-003 ENST00000382989 0.12 (0.05) 0.0176 0.16 (0.08) 0.038 
34 MME-AS1-001 ENST00000484721 1.30 (0.43) 0.0055 1.98 (0.69) 0.0074 
35 NDNF-001 ENST00000379692 0.38 (0.14) 0.0092 0.64 (0.21) 0.0054 
36 NFASC-205 ENST00000367169 0.05 (0.02) 0.019 0.07 (0.03) 0.0347 
37 NFE2L2-015 ENST00000588123 0.19 (0.06) 0.0053 0.32 (0.10) 0.0022 
38 NPHS1-001 ENST00000378910 0.54 (0.23) 0.0289 0.85 (0.37) 0.0296 
39 NPHS2-001 ENST00000367615 2.66 (0.90) 0.0061 4.14 (1.42) 0.0068 
40 NPNT-001 ENST00000379987 0.39 (0.17) 0.0315 0.55 (0.28) 0.0564 
41 NTNG1-001 ENST00000370074 0.07 (0.02) 0.0033 0.10 (0.04) 0.0108 
42 PAH-001 ENST00000553106 0.98 (0.35) 0.0084 1.52 (0.55) 0.0095 
43 PAH-002 ENST00000307000 14.53 (5.10) 0.0079 22.75 (8.07) 0.0085 
44 PLA2R1-001 ENST00000283243 0.06 (0.03) 0.0462 0.10 (0.05) 0.0441 
45 PLA2R1-002 ENST00000392771 0.11 (0.04) 0.0145 0.15 (0.07) 0.0366 
46 PODXL-201 ENST00000537928 0.60 (0.28) 0.0379 0.89 (0.44) 0.051 
47 PTPRD-206 ENST00000397617 0.06 (0.02) 0.0309 0.10 (0.04) 0.0131 
48 PTPRO-002 ENST00000348962 0.24 (0.08) 0.006 0.36 (0.13) 0.0102 
49 RAET1E-003 ENST00000532335 0.02 (0.01) 0.0085 0.03 (0.01) 0.0163 
50 RP11-154C3.2-001 ENST00000435067 0.34 (0.09) 0.0009 0.51 (0.15) 0.0017 
51 RP11-550H2.2-001 ENST00000434540 0.06 (0.03) 0.0873 0.11 (0.05) 0.0421 
52 RP11-656E20.3-001 ENST00000541344 0.84 (0.30) 0.0085 1.18 (0.48) 0.0203 
53 RP11-752D24.2-001 ENST00000510351 0.06 (0.02) 0.0162 0.11 (0.03) 0.004 
54 RP11-752D24.2-003 ENST00000504048 0.05 (0.01) 0.0008 0.08 (0.02) 0.0004 
55 RP11-849I19.1-001 ENST00000575722 0.10 (0.05) 0.0468 0.18 (0.08) 0.0332 
56 RP11-849I19.1-002 ENST00000572007 0.07 (0.03) 0.0224 0.12 (0.05) 0.0114 
57 RPS24P17-001 ENST00000479895 0.40 (0.14) 0.006 0.69 (0.21) 0.0025 
58 SCN7A-001 ENST00000409855 0.01 (0.01) 0.0824 0.02 (0.01) 0.0408 
59 SLC12A1-010 ENST00000559723 0.24 (0.11) 0.03 0.32 (0.17) 0.0727 
60 SLC12A3-001 ENST00000438926 2.85 (0.96) 0.0058 4.74 (1.49) 0.0035 
61 SLC12A3-003 ENST00000262502 3.02 (0.99) 0.0047 4.82 (1.55) 0.0042 
62 SLC12A3-007 ENST00000563352 1.05 (0.38) 0.0095 1.80 (0.58) 0.0044 
63 SLC22A8-001 ENST00000336232 18.75 (7.64) 0.0203 29.80 (12.05) 0.0194 
64 SLC36A2-201 ENST00000450886 2.36 (0.92) 0.0156 3.95 (1.43) 0.01 
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65 SLC7A8-008 ENST00000397310 3.02 (1.27) 0.0242 4.48 (2.03) 0.0349 
66 SOST-001 ENST00000301691 0.33 (0.13) 0.0156 0.54 (0.20) 0.0136 
67 SPOCK2-004 ENST00000373109 0.02 (0.01) 0.0182 0.02 (0.01) 0.0844 
68 TCF24-001 ENST00000563496 0.01 (0.00) 0.0202 0.02 (0.01) 0.0049 
69 TGFBR3-201 ENST00000212355 0.15 (0.07) 0.0396 0.21 (0.11) 0.0603 
70 TMEM52B-005 ENST00000543484 0.59 (0.25) 0.0237 0.88 (0.39) 0.0338 
71 TNNT2-001 ENST00000367322 0.46 (0.16) 0.0076 0.72 (0.25) 0.0082 
72 TSPAN2-001 ENST00000369516 0.05 (0.02) 0.0175 0.07 (0.03) 0.0457 
73 TYRO3-001 ENST00000263798 0.15 (0.05) 0.0052 0.24 (0.08) 0.0049 
74 WNK1-201 ENST00000340908 0.43 (0.11) 0.0005 0.62 (0.18) 0.0018 
75 WT1-004 ENST00000452863 0.04 (0.02) 0.014 0.06 (0.03) 0.0244 
Data are β-coefficients, standard errors (SE) and level of statistical significance (P-value) from linear regression models wherby clinic blood pressure 
(adjusted for treatment) was a dependent variable, and mRNA expression level (in TPM units) for individual mRNAs, age, sex and BMI were independent 
parameters, TRANSLATE – TRANScriptome of renaL humAn TissueE Study 
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Table S9. FGF1-co-expressed genes that show association with clinic blood pressure in TRANSLATE Study and have direct prior annotation to blood 
pressure regulation either through Gene Ontology (GO:0008217) and its ancestor terms or by manual data mining. 
No 
Gene 
symbol 
Gene name Annotation Relevance  to blood pressure regulation 
Direction of association 
with expression of FGF1 
1 MME 
Membrane metallo-
endopeptidase 
GO 
● glycoprotein particularly abundant in kidney, where it is 
present on glomerular epithelium and the brush border of 
proximal tubules 
● acts as a neutral endopeptidase cleaving peptides at the 
amino side of hydrophobic residues 
● drives catabolism of vasoactive peptides involved in 
diuresis and natriuresis including natriuretic peptides, 
angiotensin I, bradykinin, and endothelin-1 
● pharmacological inhibition of MME was/is used in therapy 
of hypertension and heart failure (candoxatril, omapatrilat) 
+ 
2 PTPRO 
Protein tyrosine 
phosphatase, receptor type, 
O 
GO 
● encodes a protein known as Glomerular Epithelial Protein 
1 
● inhibits cell proliferation and facilitates apoptosis 
● possesses tyrosine phosphatase activity 
● plays a role in regulating the glomerular pressure/filtration 
rate relationship through an effect on podocyte structure and 
function 
+ 
3 REN Renin GO 
● rate-limiting enzyme of renin-angiotensin system - 
responsible for conversion of angiotensinogen into 
angiotensin I 
● an activator of the main pathway of blood pressure 
regulation 
● in the kidney expressed primarily within the juxta-
glomerular apparatus (from where it is released into 
circulation) and the distal nephron (local renin-angiotensin 
system) 
● a target for pharmacological antihypertensive treatment 
(aliskiren) 
+ 
4 SLC12A3 
Solute carrier family 12 
(sodium/chloride 
transporters), member 3 
Manual 
● encodes thiazide-sensitive sodium-chloride co-transporter 
(NCCT) 
● key mediator of sodium and chloride reabsorption - it 
+ 
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accounts for a significant fraction of renal sodium 
reabsorption 
● expressed primarily within the distal portion of the tubular 
epithelium 
● genetic mutations in this gene are known to cause 
Mendelian form of low blood pressure (Gitelman syndrome) 
● a target for thiazide diuretics 
5 WNK1 
WNK lysine deficient 
protein kinase 1 
GO 
● member of the WNK (With No K, K = lysine residue) 
family of serine-threonine kinases 
● a key regulator of the Na-Cl co-transporter, NCCT 
(encoded by SLC12A3 gene) responsible for sodium 
reabsorption in the distal convoluted tubule and the linked 
process of potassium secretion by the renal outer medullary 
potassium channel  
● mutations in this gene are recognised  cause of 
pseudohypoaldosteronism type 2 (PHA2), also known as 
Gordon’s syndrome (an autosomal dominant disorder of 
elevated blood pressure hyperkalaemia, despite normal renal 
glomerular filtration) 
+ 
GO – gene ontology, TRANSLATE – TRANScriptome of renaL humAn TissueE Study, + stands for positive 
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Table S10. Enrichment for glomerular expression among genes associated with renal expresion of 
FGF1 and with the strongest relevance to blood pressure regulation. 
Number Gene Glomerular enrichment References 
 FGF1 ++++ 21-24 
1 MME ++++ 21-24 
2 PTPRO ++++ 21-24 
3 REN + 23 
4 SLC12A3   
5 WNK1   
+ refers to the positive enrichement in one in four referenced resources 
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Supplementary Figures 
 
Figure S1. Regional linkage disequilibrium plot of rs152524 with 1Mb-surrounding chromosomal 
region. On Y axis – r
2
 – a coefficient of linkage disequilibrium; on X axis – single nucleotide 
polymorphisms from 1000 Genomes pilot 1 project within 500 Kb distance on each side of  rs152524 
– information based on CEU population; in grey – single nucleotide polymorphisms in a weak linkage 
disequilibrium with rs152524; in yellow/orange – single nucleotide polymorphisms in a moderately 
strong linkage disequilibrium with rs152524; in red – single nucleotide polymorphisms in the highest 
linkage disequilibrium with rs152524; genes in the regions are shown as grey bars; above in red – 
gene symbols. 
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Figure S2. Partner genes of FGF1 in the kidney – next-generation RNA-sequencing in 
TRANScriptome of renaL humAn TissueE (TRANSLATE) Study. Outermost circle – symbols of 506 
genes whose transcripts are associated with renal expression of FGF1; first circle below – level of 
renal expression for each partner genes (in log2 TPM+1 values) whereby white – lowest expression 
and navy blue – highest expression; second circle below – level of co-expression (measured as β-
coefficient from linear regression) between each partner gene and FGF1 whereby dark brown – strong 
positive co-expression and beige – weak positive co-expression; third circle below – level of 
statistical significance (measured as –log10 P-value from linear regression) for co-expression between 
each partner gene and FGF1, whereby white – strong statistical significance and pink – weak 
statistical significance; most inner circle – level of connectivity of partner genes whereby dark red – 
highly connective genes, orange – genes with low connectivity. 
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Figure S3. Replicated partner mRNAs of FGF1 in the kidney – next-generation RNA-sequencing in 
The Cancer Genome Atlas resource (TCGA). Replicated mRNAs – mRNAs associated with 
expression of FGF1 in both the TRANScriptome of renaL humAn TissueE Study and  TCGA; 
outermost circle – symbols of 126 mRNAs ordered in circular manner; first circle below – level of 
renal expression for each replicated partner mRNA (in log2 TPM+1 values) whereby white – lowest 
expression and navy blue – highest expression; second circle below – level of co-expression 
(measured as β-coefficient from linear regression) between each partner mRNA and FGF1 mRNA 
whereby dark brown – strong positive co-expression and beige – weak positive co-expression; third 
circle below – level of statistical significance (measured as –log10 P-value from linear regression) for 
co-expression between each partner mRNA and FGF1 mRNA, whereby white – strong statistical 
significance and pink – weak statistical significance; most inner circle – level of connectivity of 
partner mRNAs whereby dark red – highly connective mRNAs, orange – mRNAs with low 
connectivity; inside – co-expression between selected mRNAs relevant to blood pressure regulation. 
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Figure S4. A total of 126 mRNAs co-expressed with FGF1 in the human kidney – consistency in the 
regression β-coefficient (as a measure of association of FGF1 mRNA with partner mRNAs) between 
the discovery population (TRANScriptome of renaL humAn TissueE – TRANSLATE Study) and the 
replication resource (The Cancer Genome Atlas – TCGA), log2 TPM+1 – unit of expression from 
next-generation RNA-sequencing. 
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